Table 2. Detailed information of hub areas in differentially covaried network of CHB.
| Involved pathway/function | Metabolites/Covariations | Change in CHB* | Significance** | |
|---|---|---|---|---|
| Glycine metabolism | Glycine synthesis | Glycine(S) | 0.68 (76.6%) | P = 0.00026 |
| Glycine(U)—Glycerate(S) | Decreased (0.55→-0.085) | Z = -3.33 | ||
| Phenolic compound metabolism | Glycine(U)—4-Hydroxyhippurate(U) | Increased (-0.11→0.49) | Z = 3.57 | |
| Tyrosine(S) | 1.43 (66.2%) | P = 0.01 | ||
| Bile acid synthesis | Glycine(S)—Cholesterol(S) | Increased (-0.27→0.34) | Z = 3.71 | |
| Bile acid (Clinical indicator) | 2.30 (54.6%) | P = 1.29E-05 | ||
| Entering into TCA cycle | Glycine(S)—Malic acid(S) | Increased (-0.58→0.19) | Z = -4.16 | |
| TCA cycle | Fatty acids~ TCA cycle | Succinate(S)—Oleic acid(S) | Decreased (0.70→0.007) | Z = -3.30 |
| Citrate(U)—Glycerol 1-octadecanoate(S) | Decreased (0.59→-0.026) | Z = -2.99 | ||
| Fatty acids | Hexadecanoic acid(S) | 1.65 (75.9%) | P = 0.0019 | |
| Oleic acid | 1.61 (75.2%) | P = 0.0031 | ||
| Stearic acid(S) | 1.43 (68.3%) | P = 0.0075 |
* For metabolites, the data is presented as the fold change (CHB/health) followed by proportion of CHB patients showing higher/lower level than the average value of healthy controls. For covariations, the data is presented as increased/decreased (Corhealth → CorCHB).
** For metabolites, the significance was measured by P-value from two tailed student’s t test; and for covariations, Z-score was used instead. A significant difference between CHB group and healthy control exists if p-value < 0.05 or |Z| > 3.